Tamar Geiger
YOU?
Author Swipe
View article: Integrated spatial proteomic analysis of breast cancer heterogeneity unravels cancer cell phenotypic plasticity
Integrated spatial proteomic analysis of breast cancer heterogeneity unravels cancer cell phenotypic plasticity Open
Tumor heterogeneity drives drug resistance and relapse, influencing immune evasion and tumor progression. While intratumor heterogeneity has been extensively studied at the genomic level, its functional outcomes and interactions with the t…
View article: High-Throughput Single-Cell Proteomics of In Vivo Cells
High-Throughput Single-Cell Proteomics of In Vivo Cells Open
Single-cell mass spectrometry-based proteomics (SCP) can resolve cellular heterogeneity in complex biological systems and provide a system-level view of the proteome of each cell. Major advancements in SCP methodologies have been introduce…
View article: Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation
Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation Open
Nongenetic adaptive resistance to chemotherapy, driven by transcriptional rewiring, is emerging as a significant mechanism in tumor survival. In this study we combined longitudinal transcriptomics with temporal pattern analysis to investig…
View article: P53 deficiency triggers hypertranscription, inducing nucleotide insufficiency causing replication stress, and genomic instability
P53 deficiency triggers hypertranscription, inducing nucleotide insufficiency causing replication stress, and genomic instability Open
Summary P53 prevents DNA damage by inducing repair processes, cell cycle arrest or apoptosis. P53 loss leads to replication stress and genomic instability, yet the mechanisms underlying these effects and their contribution to catastrophic …
View article: A Novel Algorithm for the Harmonization of Pan-cancer Proteomics
A Novel Algorithm for the Harmonization of Pan-cancer Proteomics Open
Proteomic characterization of cancer tissues holds the potential to advance therapeutic options and reveal novel biomarkers by unlocking insights available only on the proteome level. However, proteomics data analysis is greatly challenged…
View article: Why do few women choose IT-related programmes? A study of gender-specific perceptions and preferences in the context of business informatics
Why do few women choose IT-related programmes? A study of gender-specific perceptions and preferences in the context of business informatics Open
Purpose Digital transformation is a key factor in the competitiveness of modern businesses. However, the shortage of IT specialists poses a significant challenge. The significant underrepresentation of women in IT-related programmes in hig…
View article: High throughput single-cell proteomics of in-vivo cells
High throughput single-cell proteomics of in-vivo cells Open
Single-cell mass spectrometry-based proteomics (SCP) can resolve cellular heterogeneity in complex biological systems and provide a system-level view of the proteome of each cell. Major advancements in SCP methodologies have been introduce…
View article: Supplementary Figure 8 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Supplementary Figure 8 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Supplementary Figure 8
View article: Supplementary Figure 3 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Supplementary Figure 3 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Supplementary Figure 3
View article: Table S6 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S6 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Differential gene expression analysis between Interferon Resistance Score (IRS) high and low tumors in four melanoma cohorts. Related to Figure 2.
View article: Table S1 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S1 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Primers and Antibodies used in this paper.
View article: Table S2 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S2 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Patients’ clinical data.
View article: Table S3 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S3 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Comparison between proteome and transcriptome profiling. Related to Figure 1.
View article: Supplementary Figure 6 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Supplementary Figure 6 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Supplementary Figure 6
View article: Supplementary Figure 3 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Supplementary Figure 3 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Supplementary Figure 3
View article: Supplementary Figure 7 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Supplementary Figure 7 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Supplementary Figure 7
View article: Table S6 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S6 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Differential gene expression analysis between Interferon Resistance Score (IRS) high and low tumors in four melanoma cohorts. Related to Figure 2.
View article: Table S4 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S4 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Similarity between TIL ACT and PD-1 blockade response mechanism. Related to Figure S1.
View article: Table S4 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S4 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Similarity between TIL ACT and PD-1 blockade response mechanism. Related to Figure S1.
View article: Table S1 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S1 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Primers and Antibodies used in this paper.
View article: Supplementary Figure 5 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Supplementary Figure 5 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Supplementary Figure 5
View article: Supplementary Figure 2 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Supplementary Figure 2 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Supplementary Figure 2
View article: Table S5 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S5 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Differential gene expression analysis between responders and non-responders to immunotherapy. Related to Figure 1.
View article: Table S3 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S3 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Comparison between proteome and transcriptome profiling. Related to Figure 1.
View article: Table S5 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S5 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Differential gene expression analysis between responders and non-responders to immunotherapy. Related to Figure 1.
View article: Table S2 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Table S2 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Patients’ clinical data.
View article: Data from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Data from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Immunotherapy has revolutionized the treatment of advanced melanoma. Because the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of pre-immunotherapy tumor biopsies from melanoma pat…
View article: Supplementary Figure 2 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Supplementary Figure 2 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2 Open
Supplementary Figure 2